ARTICLES BY MATTHEW PILLAR
-
Democratizing Biologics With Lumen Bioscience's Brian Finrow, J.D. & Craig Behnke, Ph.D.11/28/2021
Lumen Bioscience's cofounder and CEO, Brian Finrow, J.D., and EVP of production/development, Craig Behnke, Ph.D., discuss the development of therapeutic proteins from readily available food algae spirulina. It's driving a diverse pipeline of candidates into the clinic, for indications reaching from the gut to the heart and lungs.
-
The Real Threat To Biopharma Supply Chains: Bioprocessing Materials5/12/2020
The COVID-19 induced risk to biopharma is not a shortage of pharmaceutical ingredients. It’s the constricting supply of consumable materials and equipment necessary to produce therapies from them. Mike Piccarreta, Partner at Kearney, offers an outlook and practical advice on supply stabilization in this BioProcess Online exclusive.
-
ILC Therapeutics’ Interferon Alpha 14 Joins The COVID-19 Fight5/5/2020
The Glasgow-based emerging biopharma recently tapped veteran biotech leader Alan Walker as CEO as it moves ahead with two therapeutic candidates, an rIFN alpha14 focused on early-stage COVID-19 infection and a tick-derived Evasin targeting late-stage COVID-19 ARDS patients.
-
Does Gender Disparity In Biotech Really Matter?9/3/2019
Why it does, and how one startup is winning the biotech talent wars with a diversity-centric strategy.